Our Team

Paul H. Schwartz, DVM, CEO is a Doctor of Veterinary Medicine with practices throughout New York. He is accomplished in the care of small animals. In his practice, he has remained on the forefront with the development of new procedures and technologies in veterinary science. Dr. Schwartz is experienced in bringing new technologies to market and running several for profit enterprises.

I have enjoyed a reasonably successful career as an innovation leader in the pharmaceutical industry. My research spans development and innovative aspects of iagnostic tests, Nutraceutical and drug delivery for the past 30 years. I have started 4 pharmaceutical companies two in USA and two in India. I own three patents. Our innovative drug delivery system is to improve 45% approved drugs, which are compromised in delivery system that leads to high toxicity. I have designed a system where not only we can improve the efficacy but reduce the toxicity of drug.I am passionate about advancing treatment of the deadliest.

Past President and Founder of Woodland Pharmaceuticals, LLC Adjunct Professor of Environmental and Population Health, Tufts University School of Veterinary Medicine Director level in Pfizer, Pharmacia, GSK and Ligand Pharmaceuticals Postdoctoral Fellow, University of Texas Southwestern Medical Center, laboratory of Nobel Laureates Drs. Michael Brown and Joseph Goldstein EMBO Fellow, Universitat Zurich, Lab of Dr. Ernst Hafen Ph.D. University of California, Berkeley, laboratory of Prof. Robert Tjian B.A. Biology, University of Delaware, Dean’s Scholar.

I have 27 years of postgraduate experience as a surgeon-scientist and expertise in the caring for patients with diseases of the liver, pancreas, and gallbladder, and now primarily focus on the management of patients with pancreatic cancer. After emigrating to Cleveland 5 years ago, and having established both my clinical practice and an active clinical research program, I established a Pancreatic Translational Research Group (PTRG) within the Lerner Research Institute that crossed all disciplines of basic science research within the institution and linked the scientists with clinicians at the Cleveland Clinic. More recently I expanded the group to cover all hospital systems and research institutions in Cleveland renaming the collaboration the Cleveland Pancreatic Translational Research Group (CPTRG). The CPTRG is integrally linked with the National Cancer Institute (NCI) designated Case